Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Fecal Microbiota Alterations of Adalimumab Efficacy in Patients with Crohn's Disease

PROVIDER: PRJNA806451 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18000046_1.fastq.gz	Fastqsanger.gz
	SRR18000046_2.fastq.gz	Fastqsanger.gz
	SRR18000047_1.fastq.gz	Fastqsanger.gz
	SRR18000047_2.fastq.gz	Fastqsanger.gz
	SRR18000048_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

Project description:Fecal microbiota predicts postoperative endoscopic recurrence in patients with Crohn's disease

| PRJNA800594 | ENA

Impact of fecal microbiota transplantation (FMT) in 3 days-ABX-treated recipient mice using feces from 6 NSCLC patients at diagnosis.

Project description:This study aimed to analyze changes in gut microbiota composition in mice after transplantation of fecal microbiota (FMT, N = 6) from the feces of NSCLC patients by analyzing fecal content using 16S rRNA sequencing, 10 days after transplantation. Specific-pathogen-free (SPF) mice were used for each experiments (N=4) as controls.

2023-07-01 | E-MTAB-12812 | biostudies-arrayexpress

Project description:The fecal microbiota and disease activity in Crohn's disease

| PRJEB11845 | ENA

Disease Severity and Immune Activity Relate to Inter-Kingdom Gut Microbiome States in Ethnically Distinct Ulcerative Colitis Patients

Project description:Significant gut microbiota heterogeneity exists amongst UC patients though the clinical implications of this variance are unknown. European and South Asian UC patients exhibit distinct disease risk alleles, many of which regulate immune function and relate to variation in gut microbiota Î²-diversity. We hypothesized ethnically distinct UC patients exhibit discrete gut microbiotas with unique luminal metabolic programming that influence adaptive immune responses and relate to clinical status. Using parallel bacterial 16S rRNA and fungal ITS2 sequencing of fecal samples (UC n=30; healthy n=13), we corroborated previous observations of UC-associated depletion of bacterial diversity and demonstrated significant gastrointestinal expansion of Saccharomycetales as a novel UC characteristic. We identified four distinct microbial community states (MCS 1-4), confirmed their existence using microbiota data from an independent UC cohort, and show they co-associate with patient ethnicity and degree of disease severity. Each MCS was predicted to be uniquely enriched for specific amino acid, carbohydrate, and lipid metabolism pathways and exhibited significant luminal enrichment of metabolic products from these pathways. Using a novel in vitro human DC/T-cell assay we show that DC exposure to patient fecal water led to MCS -specific changes in T-cell populations, particularly the Th1:Th2 ratio, and that patients with the most severe disease exhibited the greatest Th2 skewing. Thus, based on ethnicity, microbiome composition, and associated metabolic dysfunction, UC patients may be stratified in a clinically and immunologically meaningful manner, providing a platform for the development of FMC-focused therapy. Fecal microbiome was assessed with Affymetrix PhyloChip arrays from patients with ulcerative colitis and healthy controls.

2016-07-25 | E-GEOD-78724 | biostudies-arrayexpress

human gut metagenome

Project description:Gut microbiota from patients with Crohn's disease

| PRJNA296946 | ENA

Project description:Fecal fungal microbiota alterations associated with clinical phenotypes in Crohn's disease in southwest China

| PRJNA861876 | ENA

16S Analysis of Poly I:C treated mouse to induce ASD

Project description:Fecal Microbiota rawdata from autistic model mice. Female and Male Poly I:C treated mice were compared at microbiota level.

2023-05-04 | E-MTAB-11150 | biostudies-arrayexpress

Transcriptomic signature of white adipose tissue from wild type and Acod1-deficient mice in response to high fat diet

Project description:Aconitate decarboxylase 1 (ACOD1) is the enzyme synthesizing itaconate, an immuno-regulatory metabolite tuning host-pathogen interactions. Such functions are achieved by affecting metabolic pathways regulating inflammation and microbe survival. However, at the whole-body level, metabolic roles of itaconate remain largely unresolved. By using multiomics-integrated approaches, here we show that ACOD1 responds to high-fat diet consumption in mice by promoting gut microbiota alterations supporting metabolic disease. Genetic disruption of itaconate biosynthesis protects mice against obesity, alterations in glucose homeostasis and liver metabolic dysfunctions by decreasing meta-inflammatory responses to dietary lipid overload. Mechanistically, fecal metagenomics and microbiota transplantation experiments demonstrate such effects are dependent on an amelioration of the intestinal ecosystem composition, skewed by high-fat diet feeding towards obesogenic phenotype. In particular, unbiased fecal microbiota profiling and axenic culture experiments point towards a primary role for itaconate in inhibiting growth of Bacteroidaceae and Bacteroides, family and genus of Bacteroidetes phylum, the major gut microbial taxon associated with metabolic health. Specularly to the effects imposed by Acod1 deficiency on fecal microbiota, oral itaconate consumption enhances diet-induced gut dysbiosis and associated obesogenic responses in mice. Unveiling an unrecognized role of itaconate, either endogenously produced or exogenously administered, in supporting microbiota alterations underlying diet-induced obesity in mice, our study points ACOD1 as a target against inflammatory consequences of overnutrition.

2024-02-05 | GSE213632 | GEO

IBD200: Multi-omics of IBD Severity Study

Project description:This study contains multiple -omic data sets. As a follow up to a study on 40 Ulcerative Colitis patients (MSV000082094), 210 fecal samples were analyzed through proteomics using Tandem Mass Tag (TMT) MS3 quantitation. Samples include both Ulcerative Colitis and Crohn's disease patients with healthy volunteers for context. Fecal samples were also analyzed by metabolomics through LCMS2 on a Bruker Maxis qTOF.

2020-11-23 | MSV000086509 | MassIVE

Project description:Oral and gut microbiota of Crohn's disease patients

| PRJNA831448 | ENA